Amarin Corporation (AMRN) Q1 2025 earnings summary

Executive summary

• Achieved foundational progress in global expansion, cost management, and operational efficiency, with a focus on maximizing VASCEPA/VAZKEPA value and maintaining a strong balance sheet.

• Expanded Vascepa's reach from 7 to 21 reimbursed and launched countries since Q1 2023, with notable progress in Italy, Austria, China, Australia, and Saudi Arabia.

• Maintained a debt-free balance sheet and strong cash position, with $282 million in cash and investments as of March 31, 2025.

• Regained Nasdaq listing compliance via a 1-for-20 ADS ratio change.

• Ongoing efforts target expanded reimbursement, market access, and international partnerships.

Financial highlights

• Q1 2025 total net revenue was $42.0 million, down 26% year-over-year from $56.5 million, mainly due to lower U.S. net selling price and volume amid generic competition.

• U.S. product revenue declined to $35.7 million from $48.1 million year-over-year, while European product revenue grew to $5.4 million from $1.9 million, driven by demand in Spain, the U.K., and Central Eastern Europe.

• Gross margin improved to 59% from 55% year-over-year, reflecting changes in customer mix.

• Net loss for Q1 2025 was $15.7 million, compared to $10.0 million in Q1 2024.

• Operating expenses were $41.9 million, an 8% reduction year-over-year.

Outlook and guidance

• Anticipates continued year-over-year U.S. revenue declines due to generic competition, but expects to extract value through focused execution and global expansion.

• Expects variability and choppiness in rest of world revenues as new markets ramp up, but remains optimistic about long-term growth.

• Plans to continue investing in scientific data generation, market access, and operational discipline to support Vascepa's differentiation and expansion.

• Cash reserves are expected to fund operations and the share repurchase program for at least one year.

• Anticipates first regulatory approvals in new ROW markets in 2026.